PFE
http://bit.ly/93O06I $PFE Drugmakers Pfizer, Roche Disappoint With Forecasts
PFE
http://bit.ly/c4azSL $PFE Pfizer Misses Estimates, and Shares Slide
PFE
$pfe : Katsenelson likes the company.perfect stock for this economy.http://bit.ly/9pX5Uv #stocks
PFE
$PFE Like California's state govt, it has become place to stash political hacks & retreads in between elections. http://bit.ly/dxvQeT
PFE
Pfizer Inc $PFE Somewhat Down. Allens acts for Pfizer on divestment of animal health assets: http://bit.ly/d9eVLw
PFE
Pfizer Inc $PFE Somewhat Down. Chartpoppers.com releases Investment Analysis on Bristol Mye: http://bit.ly/aKk9Jz
PFE
Pfizer Inc $PFE Somewhat Down. BRIEF: Bristol-Myers freezing salaries: http://bit.ly/8X4WDG
PFE
Pfizer Inc $PFE Somewhat Down. BRIEF: Bristol-Myers freezing salaries: http://bit.ly/92Invt
PFE
$PFE, sell / short @ market,1st target $16.92, use a stop close only order above $19.26; Selling March $20 calls also warranted.
PFE
@drpdtapp $DNA's Avastin was also approved in renal cancer. All on top of $PFE's Sutent, Torisel and $ONY Nexavar
PFE
$PFE seeing lots of shares trading. http://tinyurl.com/ykw6x86
PFE
$PFE RT @ChristianeTrue @MattD19: Kindler took chance & stood on 1 side of aisle.Unfortunately,may not pay off Via @WSJ http://bit.ly/bC
PFE
RT @reutersBenHir: Will cutting research kill or cure Big Pharma? http://tinyurl.com/yc4kee8 $GSK $AZN $PFE
PFE
Will cutting research kill or cure Big Pharma? http://tinyurl.com/yc4kee8 $GSK $AZN $PFE
PFE
Trust evaporates after Pfizer's Q4 erns. RT @Jim_Edwards Wall Street furious about $PFE's numbers games. http://bit.ly/9LRDsm
PFE
Pfizer Inc $PFE Not Moving. MARKET WATCH: Global stocks close sideways on investor cauti: http://bit.ly/aQ1Tkq
PFE
Pfizer Inc $PFE Not Moving. MARKET WATCH: Global stocks close sideways on investor cauti: http://bit.ly/96eLsr
PFE
Pfizer Inc $PFE Moderately Down, Lost over 3%. Drug adopted by Pfizer OK'd: Xiaflex treats progressive: http://bit.ly/aBXhr8
PFE
spreads, but smaller does not so much. Possible to arbitrage $64B $WYE/$PFE transaction for abt 40% annualizd rates return. $SGP/$MRK was
PFE
RT @MaverickNY - RT @mhuckman: On an ugly day for the stock market Dow components Pfizer $PFE finished down 3%, Merck $MRK off 4% & J&am
PFE
RT @mhuckman: On an ugly day for the stock market Dow components Pfizer $PFE finished down 3%, Merck $MRK off 4% & J&J $JNJ -1.5%.
PFE
Berkowitz on Pharma (shifting from D to O) $PFE http://bit.ly/cBQw88
PFE
Pos dvlpmnt for nwly diag GBM patients - RT @ChristianeTrue @mhuckman $PFE $QGEN to develop EGFRvIII companion test 4 $CLDX/$PFE vaccine
PFE
RT @mhuckman: Pfizer & Qiagen $PFE $QGEN hook up on brain cancer diagnostic to see who might respond to experimental Celldex/PFE tmt. $C
PFE
On an ugly day for the stock market Dow components Pfizer $PFE finished down 3%, Merck $MRK off 4% & J&J $JNJ -1.5%.
PFE
RT @mhuckman: Pfizer & Qiagen $PFE $QGEN hook up on brain cancer diagnostic to see who might respond to experimental Celldex/PFE tmt. $C
Pfizer Inc. - PFE Insiders
No Insiders
We have no insiders for Pfizer right now.
Know someone who is an insider on Pfizer Inc.?
Let us know.
Pfizer Inc. - PFE information
Pfizer Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide. Its Pharmaceutical segment offers Lipitor for elevated cholesterol levels in the blood; Norvasc for hypertension; Caduet for cardiovascular events; Chantix/Champix for smoking cessation; Lyrica for neuropathic pain; Geodon/Zeldox, a psychotropic agent; and Aricept for Alzheimer?s disease. It also provides Celebrex for arthritis pain, and inflammation and acute pain; Vfend for esophageal candidiasis and blood stream infections; Zyvox for bacterial infections; and Selzentry/Celsentri for adults infected with only CCR5-tropic HIV-1 detectable. In addition, this segment provides Viagra for erectile dysfunction; Detrol and Toviaz for overactive bladder; Camptosar for metastatic colorectal cancer; Sutent, an oral multi-kinase inhibitor; Xalatan/Xalacom for open-angle glaucoma and ocular hypertension; and Genotropin for growth disorders. The company?s Animal Health segment offers parasiticides, anti-inflammatories, antibiotics, vaccines, antiemetics, and anti-obesity agents. It also provides Revolution/Stronghold for dogs and cats; Rimadyl for pain and inflammation associated with canine osteoarthritis and soft tissue orthopedic surgery; Clavamox/Synulox for skin and soft tissue infections; RespiSureOne/StellamuneOne to prevent pneumonia in swine; Bovi-Shield Gold for reproductive and respiratory protection; Dectomax, an injectable and pour-on formulations; Draxxin, an antibiotic for infections in cattle and swine; and Excede to treat infections in dairy cows, beef cattle, and swine. Pfizer Inc. also involves in contract manufacturing and bulk pharmaceutical chemicals businesses. It serves doctors, nurse practitioners, physician assistants, pharmacists, hospitals, pharmacy benefit managers, managed care organizations, and government agencies. The company was founded in 1849 and is headquartered in New York, New York....
www.pfizer.com
116,500 Employees
Founded in 1849
PFIZER INC (PFE:New York)
LAST $16.49 USD
CHANGE TODAY +0.0908 0.55%
VOLUME 3.0M
As of 9:44 AM 09/3/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of PFIZER INC (PFE)
|
OPEN
$16.47
|
PREVIOUS CLOSE
$16.28
|
|
|
DAY HIGH
$16.55
|
DAY LOW
$16.45
|
|
|
52 WEEK HIGH
01/20/10 - $20.36
|
52 WEEK LOW
07/1/10 - $14.00
|
|
|
MARKET CAP
132.6B
|
AVERAGE VOLUME 10 D
45.0M
|
|
|
EPS TTM
$2.27
|
SHARES OUTSTANDING
8.0B
|
|
|
EX-DATE
08/4/10
|
P/E TTM
7.3x
|
|
|
DIVIDEND
$0.72
|
DIVIDEND YIELD
4.27%
|
|
| K = Thousands M = Millions B = Billions | ||
related news
*Most active New York Stock Exchange-traded stocks
AP Digital - 09/02/2010 6:05 PM ET
Final Glance: Pharmaceuticals companies
AP Digital - 09/02/2010 6:05 PM ET
Most active New York Stock Exchange-traded stocks
AP Digital - 09/02/2010 1:18 PM ET
Midday Glance: Pharmaceuticals companies
AP Digital - 09/02/2010 1:17 PM ET
Early Glance: Pharmaceuticals companies
AP Digital - 09/02/2010 10:32 AM ET
Key developments for PFIZER INC (PFE)
Eurofarma Laboratorios Ltda. and Pfizer Confirms Collaborative Project to Develop Generic Version of Lipitor (Atorvastatin) in Brazil
09/2/2010
Eurofarma Laboratorios Ltda. and Pfizer Inc. have confirmed a collaborative project to develop a generic version of Lipitor (atorvastatin) in Brazil. As specified in the agreement, Pfizer is responsible to develop the medication, while Eurofarma will promote, distribute, and retail the drug. The product is expected to reach the market some time this month, pending drug regulator Anvisa's approval.
Pfizer Inc. Presents at 5th eDiscovery for Pharma, Biotech & Medical Device Industries Conference, Sep-13-2010 through Sep-15-2010
08/26/2010
Pfizer Inc. Presents at 5th eDiscovery for Pharma, Biotech & Medical Device Industries Conference, Sep-13-2010 through Sep-15-2010. Venue: The Hub-CHF Center, 315 Chestnut Street, Philadelphia, PA 19106-2702, United States. Presentation Date & Speakers: Sep-14-2010, Brett Durand, Director Discovery Operations, Ronke Ekwensi, Senior Director, eDiscovery & Record Information Management.
Bristol-Myers Squibb Company and Pfizer Inc. Evaluate Unmet Need in Patients with Atrial Fibrillation
08/25/2010
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 clinical trial of the investigational drug apixaban compared with acetylsalicylic acid in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the Hot Line session on August 31, 2010, in Stockholm Sweden. Atrial fibrillation is the most common serious chronic arrhythmia, affecting about 4.5 million people in Europe and 2.2 million people in the United States. Patients with AF are at five times greater risk for stroke compared with the general population. 15% of all strokes are attributable to AF, and one quarter of all strokes in persons older than 80 years are attributable to AF. In addition to treatments for heart rate and rhythm, treatment guidelines recommend that AF patients at moderate to high risk of stroke receive anticoagulation therapy with a vitamin K antagonist (VKA), such as warfarin. However, surveys of practice patterns in developed countries demonstrate that 40% to 50% of patients with AF who are at moderate or high risk for stroke do not receive VKA. The most common reason for not treating AF patients with a VKA appears to be concern about bleeding. Difficulties managing and maintaining therapeutic warfarin dosing, as well as the use of other prescription drugs that interfere with warfarin therapy are additional concerns. Currently, guidelines for the management of patients with AF recommend the use of aspirin for those who cannot take oral anticoagulants.
PFE Competitors
| Company | Last | Change |
| AmerisourceBergen Corp | $28.47 USD | +0.385 |
| Johnson & Johnson | $58.87 USD | +0.255 |
| Novartis AG | SFr.54.20 CHF | +0.50 |
| Procter & Gamble Co/The | $60.22 USD | +0.15 |
| Roche Holding AG | SFr.142.50 CHF | +2.80 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | PFE | Industry Range |
| Price/Earnings | 15.6x |
|
| Price/Sales | 2.1x |
|
| Price/Book | 1.5x |
|
| Price/Cash Flow | 10.4x |
|
| TEV/Sales | 1.1x |
|
|
PFE |
||
|
PFE transactions
| Type Date |
Target |
|
Merger/Acquisition
September 1, 2010 |
FoldRx Pharmaceuticals, Inc. |
|
Bankruptcy
August 20, 2010 |
Professional Veterinary Products Ltd. |
|
Merger/Acquisition
July 30, 2010 |
IDUN Pharmaceuticals, Inc. |
Pfizer Inc. - PFE news
Pfizer Acts on Growing Interest in Niche Drugs
2010-09-03 07:57:47
Quote: By Michael FitzhughPfizer (PFE) has agreed to by FoldRX, a privately held specialty drug developer targeting protein misfolding for an undisclosed initial payment plus milestones. The purchase builds on the drug giant's growing interest in niche drugs, a category it has begun to develop as a potential source of new revenues capable of partially stemming the losses it will incur when Lipitor goes off-patent in 2011. Pfizer has already in-licensed Protalix's (PLX) Uplyso for Gaucher's disease, a...Read article
A Look at Immunogen Beyond the T-DM1 Setback
2010-09-03 07:57:46
Quote: This target is being pursued by Pfizer (PFE) and Centocor through naked antibodies. The Centocor antibody (CNTO-95) has been in clinical trials for 8 years and is currently in a phase I study where it is given together with Avastin. Results to date were unimpressive although there were some signs of clinical activity as a single agent. IMGN388 is interesting because it is the first and only antibody drug conjugate targeting an integrin. The naked antibodies aim at disrupting the biologic activit...Read article
Pfizer Could Reface up to 1,000 Lawsuits on HRT Complications
2010-09-03 07:57:46
Quote: The Superior Court of Pennsylvania has decided that lawsuits filed by 14 women against Pfizer’s (PFE) Wyeth and Pharmacia units over links between breast cancer and hormone replacement therapies were incorrectly dismissed by a lower court. And the ruling could restore as many as 1,000 mass tort lawsuits to the docket in Phildelphia Common Pleas Court.At issue was whether Elizabeth Coleman could have reasonably known that her breast cancer was linked to one of the HRT meds she was prescribe...Read article
UPDATE - Celldex says Pfizer ends cancer vaccine deal; shrs fall
2010-09-03 07:57:45
Keywords: Healthcare Facilities / Services,Business/Public Services,United States,Healthcare,Healthcare services,Healthcare Providers / Services,Company Events,Biotechnology / Pharmaceuticals,Biotechnology / Medical Research,Pharmaceuticals - Diversified,Volatile S
Quote: Fri Sep 3, 2010 7:44am EDT* Says cancer vaccine not strategic priority for Pfizer * Worldwide rights to vaccine revert to Celldex on Nov. 1 * Celldex down 36 pct pre-market Sept 3 (Reuters) - Celldex Therapeutics Inc (CLDX.O) said
its partner Pfizer (PFE.N) ended the deal to co-develop
Celldex's cancer vaccine, its lead product, as the program was
no longer a strategic priority for the drug giant. Celldex shares were down 36 percent at $3.05 in pre-market
trade on Friday. Worldwide rights to dev...Read article
Celldex, Pfizer Split Over Brain Tumor Drug
2010-09-03 07:57:44
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: (TheStreet) --Pfizer(PFE) walked away from a partnership with Celldex Therapeutics(CLDX) to develop the small drugmaker's brain tumor vaccine CDX-110, Celldex announced Friday.Celldex has regained full rights to CDX-110 and says it intends to continue the drug's development. Pfizer decided to terminate the partnership over CDX-110 because the drug is "no longer a strategic priority" for the company, Celldex said.Celldex shares were down 36% to $3.05 in Friday's pre-market trading.Celldex license...Read article
Hedge Funds: Einhorn up more than 4% in August
2010-09-02 04:32:14
Keywords: Industries|Banking, GLRE, Greenlight Capital RE Ltd, CIT, CIT Group Inc, ESV, ENSCO PLC, PFE, Pfizer Inc, VOD, Vodafone Group Plc
Quote: AlertEmailPrintBy Alistair Barr, MarketWatchSAN FRANCISCO (MarketWatch) -- David Einhorn generated returns of more than 4% in August as equity markets slumped, according to the investment results of Greenlight Capital Re, a reinsurer that invests its premiums with the hedge fund manager.Einhorn, who runs hedge fund firm Greenlight Capital, is also chairman of Greenlight Capital Re/quotes/comstock/15*!glre/quotes/nls/glre(GLRE24.04,+0.98,+4.25%), which reinsures a variety of property and casualty...Read article
Botox maker to pay $600M to resolve investigation
2010-09-02 04:32:12
Keywords: Botox maker to pay $600M to resolve investigation, agn,pfe
Quote: and eliminates additional related litigation cost," Biegelsen wrote in a note to investors.In recent years, federal investigators have reached multibillion dollar settlements with Pfizer, Eli Lilly and other drug companies over their marketing practices.Botox is most famous for its ability to smooth frown lines on aging foreheads, but the drug -- introduced in 1989 -- is also approved to treat neck spasms, eye muscle disorders and excessive underarm sweating.Last year the drug won approval to tr...Read article
Botox maker to pay $600M to resolve investigation
2010-09-02 04:32:10
Keywords: Botox maker to pay $600M to resolve investigation, agn,pfe
Quote: and eliminates additional related litigation cost," Biegelsen wrote in a note to investors.In recent years, federal investigators have reached multibillion dollar settlements with Pfizer, Eli Lilly and other drug companies over their marketing practices.Botox is most famous for its ability to smooth frown lines on aging foreheads, but the drug -- introduced in 1989 -- is also approved to treat neck spasms, eye muscle disorders and excessive underarm sweating.Last year the drug won approval to tr...Read article
Pfizer: You'd Have to Be Sick to Touch This Drug Stock
2010-09-02 04:32:09
Quote: By Roger Nachman Don't people buy stocks because they think the stocks will go up in value? Well not Pfizer (PFE)shareholders.If you're a Pfizer shareholder, maybe you need thecompany to develop a drug that makes you smarter, because it certainlyisn't making you richer. Take a look at a 5 year chart of PFE. It's done nothing but go down.Yes I know that Pfizer pays a steepdividend yield, currently at 4.5%.So investors should feel somestability in holding these shares.But if investors just wanted ...Read article
Bristol drug cuts stroke risk by half vs aspirin-study
2010-08-31 03:34:45
Keywords: Pharmaceuticals - Diversified,Biotechnology / Pharmaceuticals,United States,Sweden,Germany,Western Europe,Europe,Chemicals,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,Nordic States,Company News item,Economic news, EC, business/financial
Quote: Tue Aug 31, 2010 2:00am EDT
* Apixaban reduces stroke by 52 pct vs aspirin - study * No significant difference in serious bleeding - study * Bristol, Pfizer race against rivals to replace warfarin By Ben Hirschler STOCKHOLM, Aug 31 (Reuters) - An experimental drug from
Bristol-Myers Squibb (BMY.N) and Pfizer (PFE.N) reduces the risk
of stroke by more than half compared with aspirin, with no
significant rise in major bleeding, researchers said on Tuesday. The results boost prospects for apixaban...Read article
Bayer drug's safety comparable to standard care-study
2010-08-31 03:34:44
Keywords: Pharmaceuticals - Diversified,Chemicals,Germany,Western Europe,Europe,Biotechnology / Pharmaceuticals,France,United States,Sweden,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,Central/Eastern Europe,Company News item,Economic news, EC, bus
Quote: Bristol-Myers Squibb (BMY.N) and Pfizer (PFE.N) also
presented new data on their experimental apixaban in stroke
prevention at the Stockholm conference. Results of a second Xarelto study looking at Bayer's drug
when given to significantly older patients as a stroke preventer
will be presented at the American Heart Association annual
meeting in November.(Reporting by Ben Hirschler; Editing by Erica Billingham)......Read article
UPDATE - US FDA releases latest list of safety issues
2010-08-30 07:22:00
Keywords: Pharmaceuticals - Diversified,Biotechnology / Pharmaceuticals,France,Western Europe,Europe,Switzerland,Emerging Market Countries,Indonesia,Pharmaceuticals - Generic / Specialty,Japan,United States,United Kingdom,Healthcare,Pharmaceuticals,Pharmaceuticals
Quote: Fri Aug 27, 2010 2:26pm EDT
* List cites drugs by Merck, Pfizer, Genentech, others * Agency in most cases says still evaluating drug(Adds details from drug list)WASHINGTON Aug 27 (Reuters) - The U.S. Food and Drug
Administration has released its latest list of possible drug
safety concerns, citing Roche's (ROG.VX) breast cancer drug
Herceptin and Sanofi Aventis' (SASY.PA) heart drug Multaq,
among others. The list, which comes out quarterly, covers safety issues
that the FDA flagged between Apri...Read article
How Does 3PAR Rank Among Takeover Battles? Not Very High
2010-08-30 07:21:59
Quote: The takeover got nasty when Pfizer made a $74.6 billion hostile bid the same day Warner-Lambert agreed to be bought by American Home Products, now known as Wyeth. Pfizer won with $112 billion including debt, and is the largest multiple-bid takeover since at least 1995, according to data provider Dealogic.
Others of note:
In January 1999, Vodafone nudged out Bell Atlantic Corp. to acquire Airtouch Communications for $61.5 billion; in March, Comcast beat out AT&T’s in a nearly $54 billi...Read article
Heart expert says cost cuts may undermine drug R&D
2010-08-30 07:21:58
Keywords: Pharmaceuticals - Diversified,Biotechnology / Pharmaceuticals,Switzerland,Western Europe,Europe,Chemicals,Germany,United States,France,Pharmaceuticals - Generic / Specialty,United Kingdom,Health / Medicine,Sweden,Italy,Greece,Spain,Healthcare,Pharmaceutic
Quote: Much of the attention is expected to focus on two new
anti-clotting pills -- Xarelto and apixaban -- being developed
by Bayer (BAYGn.DE) and Johnson & Johnson (JNJ.N), and
Bristol-Myers Squibb (BMY.N) and Pfizer (PFE.N). Both are vying
for market share against Boehringer Ingelheim's Pradaxa, which
is nearer the market as a stroke preventer. [ID:nLDE67K03L] Medical experts will also get a first look at an
experimental blood thinner called elinogrel from Novartis and
Portola, that could be a c...Read article
UPDATE - Protalix to dual list on Tel Aviv Stock Exchange
2010-08-30 07:21:56
Keywords: Israel,Middle East,Emerging Market Countries,New Issues,United States,Biotechnology / Pharmaceuticals,Health / Medicine,Biotechnology / Medical Research,Business/Public Services,Financials,Pharmaceuticals - Diversified,Asia/Pacific,Market Events,General N
Quote: Pfizer Inc (PFE.N) has acquired worlwide rights to
Protalix's experimental drug for Gaucher disease. If approved,
the drug would compete with Genzyme's (GENZ.O) top-selling
Gaucher treatment, Cerezyme. Protalix's drug has been accepted for review by the U.S.
Food and Drug Administration. Protalix is 19 percent held by Israeli company Biocell
(BCEL.TA).(Reporting by Tova Cohen; Editing by Dan Lalor)......Read article
Pfizer - Upgrades & Downgrades
2010-08-27 02:16:49
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Kevin Baker ,TheStreet Ratings
Quote: NEW YORK (TheStreet) -TheStreet Ratings' stock model upgraded Pfizer(PFE) to 'Buy' from 'Hold'. Net income at this $128 billion market cap, biopharmaceutical company rose by 9.5% to $2.5 billion in the second quarter when compared to the year earlier quarter.TheStreet Ratings released rating changes on 16 additional U.S. common stocks for August 25, 2010. In total, seven stocks were downgraded and 10 stocks have been upgraded by our stock model.Gross sales at Pfizer reached $17.3 billion in the ...Read article
Forbes Investigation: Why Big Pharma Ignores Suicide
2010-08-27 02:16:47
Quote: Nearly 35,000 people die a year from suicide, while another million people try to kill themselves. The vast majority have some sort of mental health problem.
Yet top drug companies such as Pfizer, GlaxoSmithkline and Eli Lilly routinely exclude high-risk suicidal patients from studies. Academic psychiatrists don’t study treatments for suicidal patients thanks to lack of funding and interest. University review boards are skittish about performing studies on high-risk patients thanks to...Read article
RPT-UPDATE - FDA panel to vet Boehringer blood thinner Sept 20
2010-08-27 02:16:47
Keywords: Germany,Western Europe,Europe,Biotechnology / Pharmaceuticals,Health / Medicine,United States,Regulations / Standards,Pharmaceuticals - Diversified,Chemicals,Japan,Central/Eastern Europe,Eurozone countries,General News. International News Service (Reuters
Quote: [ID:nLDE67K03L] Bayer (BAYGn.DE) cooperates with J&J (JNJ.N) while BMS
teamed up with Pfizer (PFE.N) to win a piece of a future market
that analysts say has potential for $10-$20 billion in annual
combined sales. Daiichi Sankyo (4568.T) is developing another contender pill
called Edoxaban. The date for the FDA panel's meeting puts Boehringer firmly
on track to become the first to bring its product to the U.S.
market for the prevention of strokes in patients suffering from
atrial fibrillatio...Read article
Pfizer Failure Clears Way for Small Biotech ArQule
2010-08-25 01:07:52
Keywords: cancer,non small cell lung cancer,lung cancer,cancer treatment,cancer therapy,tarceva,sutent,biotech,big pharma,pfizer stock,arqule,,MARKETS,PFE,ARQL
Quote: Sometimes one company's pain is another's gain; in this case, Pfizer'sPFE) most recent setback (of many) could clear the path for a drug from a much smaller biotech.The Big Pharma announced Monday night that its cancer drug Sutent didn't show statistically significant improvement of overall survival in second- and third-line non-small cell lung cancer patients -- the primary goal of the late-stage study. While Sutent, which is already approved for advanced kidney cancer and gastrointestinal stro...Read article
Biggest changes in NYSE short interest
2010-08-25 01:07:49
Keywords: Financials,United States,Derivatives,Equities Markets,Investing,Household products,Semiconductors / Semiconductor Equipment,Leisure Products,Semiconductors,Pharmaceuticals - Diversified,Biotechnology / Pharmaceuticals,Advanced medical equipment,Precious M
Quote: The five companies with the largest overall short positions are also
listed.
COMPANYAUG 13JULY 30NET CHANGEPCT CHANGE
-----------------------------------------------------------------------------
FIVE BIGGEST INCREASES:
Newell Rubbermaid Inc (NWL.N)46,387,23120,675,82025,711,411124.35
Advanced Micro Devices (AMD.N) 100,611,35082,238,50518,372,84522.34
Pfizer Inc (PFE.N)69,208,98353,622,66215,586,32129.07
Boston Scientific Corp (BSX.N)64,356,09150,009,10314,346,98828.69
Kinross Gold Corp (KGC.N)1...Read article